A Randomized Trial of Simplified Maintenance Therapy with Abacavir, Lamivudine, and Zidovudine in Human Immunodeficiency Virus Infection | Zendy

Milos Opravil | Zendy; Bernard Hirschel | Zendy; Adriano Lazzarin | Zendy; Hansjakob Furrer | Zendy; JeanPhilippe Chave | Zendy; Sabine Yerly | Zendy; Leslie R. Bisset | Zendy; Marek Fischer | Zendy; Pietro Vernazza | Zendy; Enos Bernasconi | Zendy; Manuel Battegay | Zendy; Bruno Ledergerber | Zendy; Huldrych F. Günthard | Zendy; Colin Howe | Zendy; Rainer Weber | Zendy; Luc Perrin | Zendy

Open Access

A Randomized Trial of Simplified Maintenance Therapy with Abacavir, Lamivudine, and Zidovudine in Human Immunodeficiency Virus Infection

Author(s) -

Milos Opravil,

Bernard Hirschel,

Adriano Lazzarin,

Hansjakob Furrer,

JeanPhilippe Chave,

Sabine Yerly,

Leslie R. Bisset,

Marek Fischer,

Pietro Vernazza,

Enos Bernasconi,

Manuel Battegay,

Bruno Ledergerber,

Huldrych F. Günthard,

Colin Howe,

Rainer Weber,

Luc Perrin

Publication year - 2002

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/340312

Subject(s) - zidovudine , lamivudine , abacavir , regimen , reverse transcriptase inhibitor , medicine , virology , tolerability , resistance mutation , adverse effect , reverse transcriptase , sida , biology , viral disease , virus , hepatitis b virus , polymerase chain reaction , biochemistry , gene

This randomized study evaluated the efficacy and tolerability of continued treatment with protease inhibitor plus nucleoside-analogue combination regimens (n=79) or a change to the simplified regimen of abacavir-lamivudine-zidovudine (n=84) in patients with suppressed human immunodeficiency virus type 1 (HIV-1) RNA for > or = 6 months who did not have the reverse transcriptase 215 mutation. After a median follow-up of 84 weeks, virologic failure was 6% in the continuation and 15% in the simplified group (P=.081). Previous zidovudine monotherapy or dual therapy and archived reverse transcriptase resistance mutations in HIV-1 DNA at baseline were significant predictors of failure. Study treatment was discontinued because of adverse events in 20% of the continuation and 7% of the simplified group (P=.021). Simplification to abacavir-lamivudine-zidovudine significantly decreased nonfasting cholesterol and triglyceride levels; however, this switch strategy carries a risk of virologic failure when treatment history or resistance testing suggest the presence of archived resistance mutations to the simplified regimen.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research